Atlas Trials

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Clinical trial NCT05939414 · RECRUITING

Trial details

NCT number
NCT05939414
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Oligometastatic Prostate Cancer (OMPC)
Start date
2024-03-12
Primary completion
2028-04-25
Enrollment
450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.